Purinoceptor P2Y12: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In biochemistry and signal transduction, '''purinoceptor P2Y<sub>12</sub>''' is a G-protein-coupled receptor (a cell surface receptor). It is a subtype of [[purinergic P2 r...) |
imported>Daniel Mietchen (+subpages) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{subpages}} | |||
In [[biochemistry]] and [[signal transduction]], '''purinoceptor P2Y<sub>12</sub>''' is a [[G-protein-coupled receptor]] (a [[cell surface receptor]]). It is a subtype of [[purinergic P2 receptor]] that is a "receptor for [[Adenosine diphosphate|ADP]] and [[Adenosine triphosphate|ATP]] coupled to G-proteins that inhibit the adenylyl cyclase [[second messenger system]]; not activated by UDP and UTP; involved in platelets aggregation; a potential target for the treatment of [[thromboembolism]]s and other clotting disorders."<ref>{{MeSH}}</ref> | In [[biochemistry]] and [[signal transduction]], '''purinoceptor P2Y<sub>12</sub>''' is a [[G-protein-coupled receptor]] (a [[cell surface receptor]]). It is a subtype of [[purinergic P2 receptor]] that is a "receptor for [[Adenosine diphosphate|ADP]] and [[Adenosine triphosphate|ATP]] coupled to G-proteins that inhibit the adenylyl cyclase [[second messenger system]]; not activated by UDP and UTP; involved in platelets aggregation; a potential target for the treatment of [[thromboembolism]]s and other clotting disorders."<ref>{{MeSH}}</ref> | ||
==Clinical role== | |||
Blockers of P2Y<sub>12</sub> include the [[thienopyridine]]s [[clopidogrel]] and [[prasugrel]] which are irreversible and require at least 1 hour or longer to inhibit platelets. [[Cangrelor]] is a reversible blocker that acts quicker. | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Latest revision as of 09:48, 14 December 2009
In biochemistry and signal transduction, purinoceptor P2Y12 is a G-protein-coupled receptor (a cell surface receptor). It is a subtype of purinergic P2 receptor that is a "receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system; not activated by UDP and UTP; involved in platelets aggregation; a potential target for the treatment of thromboembolisms and other clotting disorders."[1]
Clinical role
Blockers of P2Y12 include the thienopyridines clopidogrel and prasugrel which are irreversible and require at least 1 hour or longer to inhibit platelets. Cangrelor is a reversible blocker that acts quicker.
References
- ↑ Anonymous (2024), Purinoceptor P2Y12 (English). Medical Subject Headings. U.S. National Library of Medicine.